BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37975819)

  • 41. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
    Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CMV-Specific Cell-Mediated Immunity in Immunocompetent Adults with Primary CMV Infection: A Case Series and Review of the Literature.
    Chiereghin A; Verucchi G; Lazzarotto T
    Viruses; 2021 May; 13(5):. PubMed ID: 34062875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.
    Egli A; Binet I; Binggeli S; Jäger C; Dumoulin A; Schaub S; Steiger J; Sester U; Sester M; Hirsch HH
    J Transl Med; 2008 Jun; 6():29. PubMed ID: 18541023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
    Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
    Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation.
    Kumar D; Mian M; Singer L; Humar A
    Am J Transplant; 2017 Sep; 17(9):2468-2473. PubMed ID: 28500691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
    Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
    Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
    Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
    Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
    Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
    Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of HLA A, B, C, DR alleles and HLA haplotypes on cytomegalovirus-specific cell mediated immunity in seropositive Korean kidney transplant candidates.
    Lee H; Kang H; Yun S; Ryu JH; Bae H; Chung BH; Yang CW; Oh EJ
    HLA; 2023 Nov; 102(5):590-598. PubMed ID: 37158113
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
    Walti CS; Krantz EM; Maalouf J; Boonyaratanakornkit J; Keane-Candib J; Joncas-Schronce L; Stevens-Ayers T; Dasgupta S; Taylor JJ; Hirayama AV; Bar M; Gardner RA; Cowan AJ; Green DJ; Boeckh MJ; Maloney DG; Turtle CJ; Hill JA
    JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33914708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of intracellular cytokine staining versus an ELISA-based assay to assess CMV-specific cell-mediated immunity in high-risk kidney transplant recipients.
    Fernández-Ruiz M; Redondo N; Parra P; Ruiz-Merlo T; Rodríguez-Goncer I; Polanco N; González E; López-Medrano F; San Juan R; Navarro D; Andrés A; Aguado JM
    J Med Virol; 2023 Apr; 95(4):e28733. PubMed ID: 37185851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.
    Mena-Romo JD; Pérez Romero P; Martín-Gandul C; Gentil MÁ; Suárez-Artacho G; Lage E; Sánchez M; Cordero E
    J Infect; 2017 Oct; 75(4):336-345. PubMed ID: 28599954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.
    Kim T; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Korean J Intern Med; 2020 Mar; 35(2):438-448. PubMed ID: 29865778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.
    Boeckh M; Leisenring W; Riddell SR; Bowden RA; Huang ML; Myerson D; Stevens-Ayers T; Flowers ME; Cunningham T; Corey L
    Blood; 2003 Jan; 101(2):407-14. PubMed ID: 12393659
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
    Lemmermann NA; Reddehase MJ
    Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.